Q2 2025 Biomx Inc Earnings Call Transcript
Key Points
- BiomX Inc (PHGE) successfully initiated patient dosing in the phase 2B clinical trial of BX 004 for cystic fibrosis, with top-line results expected in Q1 2026.
- The company published additional data from the BX004 phase 1 B2A study in Nature Communications, providing further validation of their phage therapy platform.
- BX 211 showed statistically significant results in reducing ulcer size in diabetic foot osteomyelitis patients, with strong endorsements from key opinion leaders.
- There is significant interest and enthusiasm from sites, patients, and physicians for the BX 004 study, indicating strong support for the program.
- BiomX Inc (PHGE) has ongoing collaboration discussions with the US Defense Health Agency, which has provided substantial non-dilutive funding for the BX 211 program.
- The company's cash balance decreased from $18 million at the end of 2024 to $15.2 million as of June 30, 2025, primarily due to net cash used in operating activities.
- Research and development expenses were high due to the initiation of the phase 2B clinical trial for BX 004, despite a decrease in overall R&D expenses compared to the previous year.
- General and administrative expenses decreased slightly but were offset by increased share-based compensation expenses.
- Net loss for Q2 2025 was $6 million, a significant decrease from a net income of $4.5 million in Q2 2024, mainly due to changes in the fair value of warrants.
- The company is still in the early stages of discussions with the FDA regarding the use of real-world evidence, which could impact the timeline for regulatory approval.
Good morning and welcome to the Biomx Q2, 2025 Financial results and business and program update conference call. Currently all participants are on listen-only mode. At the end of this call, there'll be a question and answer session. As a reminder, this conference call is being recorded. I would like to turn the call over to Marina Wolfson, Chief Financial Officer of Biomx. Please proceed.
Thank you and welcome to the Bionics conference call to review the company's Q2, 2025 financial results and provide an update on our business and programs.
Later today, we will file the quarterly report on Form-10Q with the Securities and Exchange Commission.
In addition, the press release became available at 6:30 a.m. Eastern time today and can be found on our website at bionics.com. A replay of this call will also be available on the investors section of our website.
As we begin, I'd like to review the safe harbor provision.
All statements on this call that are not factual historic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
